Printer Friendly

Cantabio Pharmaceuticals signs development agreement with Purdue Research Foundation.

M2 EQUITYBITES-July 13, 2016-Cantabio Pharmaceuticals signs development agreement with Purdue Research Foundation

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Cantabio Pharmaceuticals (OTCMKTS:CTBO), a biotech company, has signed a contract with Purdue Research Foundation.

It was reported yesterday that the agreement has been signed to advance the company's development work on targeting DJ-1 protein small molecule pharmaceutical chaperone drug candidates for the treatment of Parkinson's disease and other related neurodegenerative diseases.

The contract provides Cantabio with access to intellectual property derived from the joint research done at Purdue University and Cantabio, further strengthening the company's intellectual property position in DJ-1 pharmaceutical chaperones, and provides further confidence in the validity of the therapeutic program for PD and neurodegenerative diseases in general. Pharmaceutical chaperones are small molecules designed to enter cells and serve as molecular scaffolding to prevent or reverse the misfolding and loss of function of proteins. Misfolded proteins are associated with numerous diseases, particularly neurodegenerative diseases including PD and Alzheimer's disease.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 13, 2016
Words:173
Previous Article:Flagship Ventures names new chief medical officer.
Next Article:US Food and Drug Administration grants Orphan Drug Designation to NLS Pharma's narcolepsy drug Mazindol.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters